Credit and interest ratesmixed · 4 filings
“The increased interest expense was due to higher average debt balances outstanding related to the Paragon 28 acquisition.”10-Q · May 1, 2026 ↗
Zimmer Biomet Holdings, Inc.
ZBH
Market read
Zimmer Biomet Holdings, Inc.'s current read is isolated; its market group is not confirming.
The latest filing evidence is available. 0 of 20 group members are active now; 0 filing-linked outsiders are moving with the group, and 0 of 4 directly disclosed connections are confirming.
What changed
- Revenue increased 9.3% versus the comparable filing period.
Company-2.3% todayVolume comparison unavailable
Market group0 of 20 activeMedical Devices · unavailable
Disclosed network0 of 4 confirmingNo filing-linked name is confirming now
What would change this read
Watch this read- ZBH's market-adjusted activity becomes unusual and at least one connected name confirms.
Invalidation: The isolated read changes if ZBH's group or a disclosed connection begins moving with it.
Research brief
The story so far
The latest filing evidence is available. 0 of 20 group members are active now; 0 filing-linked outsiders are moving with the group, and 0 of 4 directly disclosed connections are confirming.
Evidence that supports
- Revenue increased 9.3% versus the comparable filing period.
- Operating margin improved 2.6 percentage points.
- Net income increased 30.8% versus the comparable filing period.
Evidence that challenges
No thresholded adverse filing evidence is available yet.
What would clarify the read
- ZBH's market-adjusted activity becomes unusual and at least one connected name confirms.
Company research
Understand the business, not just the ticker
Business model and earnings drivers
Use the company’s filings to identify the few operating, demand, cost, capital and regulatory variables that determine its earnings power.
Key research questions
- Which operating variable is changing?
- Is that change durable, cyclical or one-off?
- What evidence would disprove the current interpretation?
Annual periods9
Price observations601
Usable filing statements126
Verified relationships5
Evidence supporting the case
- Latest annual revenue changed +7.2% year over year.
- Operating cash flow covered net income at 2.41x in the latest annual period.
- Credit and interest rates has repeated favorable evidence across 4 filings.
- Foreign exchange has repeated favorable evidence across 4 filings.
- Product pipeline and R&D has repeated favorable evidence across 4 filings.
- Tariffs and trade policy has repeated favorable evidence across 4 filings.
Evidence challenging the case
- Operating margin changed -3.4 percentage points in the latest annual period.
- Net margin changed -3.2 percentage points in the latest annual period.
Questions before a position
No credible peer-relative valuation comparison is available yet.
Longer-term price context
Price as of Sep 10, 2026
92.396m-1.4%12m-11.0%24m-11.6%
Annual trajectory
Reported annual revenue and per-share history. This is accounting history, not a forecast.
PeriodRevenueYoYDiluted EPSShare change
2021-12-31$6.8B+11.4%$1.91+1.6%
2022-12-31$6.9B+1.6%$1.10-0.0%
2023-12-31$7.4B+6.5%$4.88-0.3%
2024-12-31$7.7B+3.8%$4.43-2.8%
2025-12-31$8.2B+7.2%$3.55-2.6%
What management says matters
Persistent and emerging business drivers
Foreign exchangepositive · 4 filings
“Our International sales were positively affected by 6.1 percent due to changes in foreign currency exchange rates in the three-month period ended March 31, 2026.”10-Q · May 1, 2026 ↗
Legal and regulatory exposuremixed · 4 filings
“The decreases were driven by completion of our spending on our initial compliance with the European Union Medical Device Regulation at the end of 2025, decreases in spending on certain projects and savings from our 2025 Restructuring Plan.”10-Q · May 1, 2026 ↗
Product pipeline and R&Dpositive · 4 filings
“2026 Outlook We expect year-over-year net sales growth of 2.5 percent to 4.5 percent in 2026 to be driven by a combination of market growth, new product introductions, the Paragon 28 acquisition and positive effects of changes in foreign currency exchange rat…”10-Q · May 1, 2026 ↗
Valuation discipline
Peer-relative valuation withheld
Jodie found no industry-matched filing peers suitable for a valuation comparison. It will not substitute broader financial-sector names.
Scenario scaffold
Mechanical 2.0-year scenarios are available as editable assumptions, not consensus.
Price action
How the market is pricing the story
92.39-2.3% today
Jodie does not have enough daily observations to draw a useful short-term chart for this asset. The latest quoted price was checked 10 Sept, 15:55 GMT-4; this is a coverage limitation, not a flat-price conclusion.
Developments
No sourced recent-development timeline yet
Jodie has not returned a relevant primary source or news item for ZBH. This is an evidence-coverage gap, not a conclusion that nothing material happened.
Business and financial condition
Reported financial figures are not available yet
Jodie has not returned structured SEC XBRL fundamentals for this asset. This is a coverage limitation, not an assessment of the business or its financial health.
Latest filing assessment · baseline
Fundamentals strengthened in the latest filing
10-Q filed 2026-05-01 against the comparable filing from 2025-05-05.
OperationsconstructiveEvidence score +3
liquidityneutralEvidence score 0
valuationmixed
What improved
- Revenue increased 9.3% versus the comparable filing period.
- Operating margin improved 2.6 percentage points.
- Net income increased 30.8% versus the comparable filing period.
What weakened
No thresholded deterioration was identified.
Filing receipts
“The decrease in operating profit as a percentage of sales was primarily due to investments in our sales force as well as higher bad debt charges.”
“The increase in net earnings was primarily due to increased net sales, a favorable adjustment of approximately $30 million related to probable U.S. tariff refunds, lower restructuring charges, lower spending on R&D projects and savings from our restructuring programs.”
“Technology & Data, Bone Cement and Surgical net sales increased 14.6 percent in the three-month period ended March 31, 2026, primarily due to strong net sales of our ROSA ® Robot and bone cement products.”
Retrospective baseline calibration. It was generated after the filing date and is not part of Jodie's live track record.
Business ecosystem
The relationships behind ZBH
Customers, suppliers, partners and competitors named in company filings—not inferred from headlines.
Depended on by
ENOVEnovis CorporationcompetitorFeb 26, 2026 ▾
“Key competitors for our Reconstructive segment include Stryker, Zimmer Biomet, and DePuy Synthes, the medical device business within Johnson & Johnson.”
Filing peers
Companies whose filings use similar operating language.
Open the three relationships above to see Jodie’s filing proof. Pro unlocks 8 more links, every receipt, and alerts when connected names begin moving. Unlock the full network →
What is moving around it
Live connections
ZBH is currently a Follower in the organic co-movement group Medical Devices. This group is discovered from market behaviour rather than assigned from an industry taxonomy. 1 filing-linked name are in the relationship map; none is currently confirmed as moving with the group.
Context history
Theme membership history
No durable theme membership has been observed for this name yet.